Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01226316 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 285
- Enrollment target
NCT01226316 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 285 participants.
The verdict
NCT01226316, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 285 participants
- Enrollment target
Study Summary
This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future. This study will also investigate how the body handles AZD5363 (ie, how quickly the body absorbs and removes the drug). This study will also investigate anti-tumour activity of AZD5363 in patients with advanced / metastatic breast, gynaecological cancers or other solid cancers bearing either AKT1 / PIK3CA or PTEN mutation.
Interventions
- DRUG AZD5363
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2010-12-01 |
| Est. Completion | 2024-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01226316
The ClinicalTrials.gov registry entry for NCT01226316 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD5363 is the first listed.
NCT01226316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01226316 about?
NCT01226316 is a clinical study titled "Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules". This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future. This study will also investigate how the body handles AZD5363 (ie, how quickly the body absorbs and removes...
What is the current status of trial NCT01226316?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 285 participants. The study started on 2010-12-01. Estimated completion is 2024-12-03.
What interventions are being tested in trial NCT01226316?
The interventions under investigation include: AZD5363 (DRUG).
Who is sponsoring clinical trial NCT01226316?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.